More Botanix Pharmaceuticals Limited news
Botanix Pharmaceuticals LimitedASX: BOT

Botanix Receives Approval for Synthetic Cannabidiol Trial

Mar 29, 2017 at 10:30 PM EDT · Issued by Botanix Pharmaceuticals Limited

Filed with ASX · Mar 29, 2017 at 10:30 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/botanix-receives-approval-for-synthetic-cannabidiol-trial

Watch Botanix Pharmaceuticals' latest call↗Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call↗

Botanix Pharmaceuticals Limited on 6ix

Earlier from Botanix Pharmaceuticals

  • Export and Import Approvals for Clinical Studies ReceivedMar 23, 2017
  • Botanix Announces Filing of New Permetrex Product PatentsFeb 26, 2017
  • Botanix Announces Expansion of Permetrex LicenseFeb 2, 2017
  • Quarterly Cashflow ReportJan 30, 2017
  • Botanix Announces Positive Human Trial DataDec 6, 2016

Later from Botanix Pharmaceuticals

  • Suspension from Official QuotationApr 3, 2017
  • Reinstatement to official quotationApr 4, 2017
  • Completion of the Tranche 1 PlacementApr 12, 2017
  • Botanix Commences First Clinical Study for BTX 1503May 7, 2017
  • Completion of Tranche 2 of Capital Raising PlacementMay 19, 2017
All Botanix Pharmaceuticals news releases↗

Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.

Follow Botanix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer